|Year : 2021 | Volume
| Issue : 1 | Page : 86-88
Ureteral carcinoma metastasizing to the testicle: Can misdiagnosis of orchiepididymitis be avoided?
Ioanna Gazouli1, Stavros Tsampalas2, Ioannis Tsimaris3, Georgios Zarkavelis1, Nikolaos Grivas4, Eleftherios Kampletsas1, Alexandra Papadaki1, Leonidas Mavroeidis1, Panagiotis Ntellas1, Stefania Gkoura1, Lampriani Tsali5, Anna-Lea Amylidi1, Maria Smaragdi Vlachou6, Davide Mauri1
1 Department of Medical Oncology, University Hospital of Ioannina; EMEKEN, Society for Study of Clonal Heterogeneity of Neoplasia, Ioannina, Greece
2 Department of Urology, University Hospital of Ioannina, Ioannina, Greece
3 Department of Urology, Chatzikosta General Hospital, Ioannina, Greece
4 Department of Urology, Chatzikosta General Hospital; European Board of Urology, Ioannina, Greece
5 PACMeR Athens, PanHellenic Association for Continual Medical Research, Ioannina, Greece
6 Medical School, University of Ioannina, Ioannina, Greece
|Date of Submission||04-Aug-2020|
|Date of Decision||21-Sep-2020|
|Date of Acceptance||02-Nov-2020|
|Date of Web Publication||19-Jan-2021|
Miss. Ioanna Gazouli
8-10, Mpizaniou Street, Ioannina 45221
| Abstract|| |
Testicular metastases from ureteral carcinoma are rare and they are generally mimic orchiepididymitis. For this reason, these are associated to misleading diagnoses and cancer treatment delay. We believe that both timing and knowledge of genital blood and lymph reverse flow routes may represent two important parameters for avoiding misleading diagnoses and speed proper anticancer treatment. We describe a case and discuss pathophysiological data and relevant literature.
Keywords: Metastasis, orchiepididymitis, testicular, upper tract urothelial carcinoma, ureter, vas deferens
|How to cite this article:|
Gazouli I, Tsampalas S, Tsimaris I, Zarkavelis G, Grivas N, Kampletsas E, Papadaki A, Mavroeidis L, Ntellas P, Gkoura S, Tsali L, Amylidi AL, Vlachou MS, Mauri D. Ureteral carcinoma metastasizing to the testicle: Can misdiagnosis of orchiepididymitis be avoided?. Urol Ann 2021;13:86-8
|How to cite this URL:|
Gazouli I, Tsampalas S, Tsimaris I, Zarkavelis G, Grivas N, Kampletsas E, Papadaki A, Mavroeidis L, Ntellas P, Gkoura S, Tsali L, Amylidi AL, Vlachou MS, Mauri D. Ureteral carcinoma metastasizing to the testicle: Can misdiagnosis of orchiepididymitis be avoided?. Urol Ann [serial online] 2021 [cited 2021 Apr 17];13:86-8. Available from: https://www.urologyannals.com/text.asp?2021/13/1/86/307371
| Introduction|| |
Primary carcinomas of the ureter, most often rise in its distal end, occurring half as often as carcinomas the renal pyelocaliceal cavities., Upper tract urothelial carcinomas (UTUCs) are generally discovered at an advanced stage, due to the thin wall of the ureter and renal pelvis, leading to a more dismal prognosis, compared to bladder cancer, and being lethal in 65% of the cases.
Data regarding the metastatic pattern of the UTUCs are scarce. In a study of 52 patients with UTUC, among whom 14 (27%) had ureteral cancer, metastatic sites were lymph nodes (75%), lungs (65%), liver (54%), bones (39%), and peritoneum (19%).
Hereby, we present a case of a male patient, with ureteral transitional carcinoma with metastatic disease to the collateral testicle, mimicking orchiepididymitis.
| Case Report|| |
A 67-year-old Caucasian male, former smoker, presented at our center, after being diagnosed with urothelial cancer of the lower left ureter, treated by robotic left ureteral nephrectomy and iliac lymph nodes resection in April 2019. The primary neoplasm was located at a distance of 0.4 cm from the ureterovesical junction, measuring 2.6 cm × 1.2 cm × 0.8 cm, and extending through the bladder cuff area. The histologic examination revealed a poorly differentiated, papillary, nodular and compact, and urothelial carcinoma, with focal necrosis and lymphovascular invasion. Immunohistochemistry was compatible with a mixed p-53-like and basal-like molecular subtype and Ki67 expression reached 30%–40%. The neoplasm infiltrated the muscular layer and the periureteral adipose tissue, while surgical limits were focally infiltrated. Eight out of the nine common iliac lymph nodes were infiltrated; the neoplasm was staged as pT3N2M0.
The patient received adjuvant chemotherapy with carboplatin and gemcitabine, from May to July 2019, and in August 2019, the patient underwent radiotherapy.
In October 2019, the patient was lamenting a painful and warm left testicular enlargement. Scrotal US and Urological examination were performed, orchiepididymitis was diagnosed and the patient was put on treatment with ciprofloxacin with a transient clinical benefit and pain reduction. in parallel, abdominal computed tomography scans [see [Figure 1],[Figure 2] evidenced local cancer progression, with malignant infiltration of the bladder, left sperm cyst, and inner iliac blood vessels. Immunotherapy with pembrolizumab was thereafter administered. In December 2019, testicular pain and enlargement of the left scrotum notably worsened, while swelling and discomfort appeared. Scrotal ultrasound revealed a cystic lesion in the center of the left testicle. Differential diagnosis between resistant orchiepididymitis or abscess was set and intravenous antibiotic treatment was again provided. Nonetheless, no improvement was noted, pain was unrelenting, and a left orchiepididymectomy was performed in January 2020. Both the left testis and epididymis were found infiltrated by the original urothelial carcinoma with a clean spermatic tone upper limit.
|Figure 1: Lower abdominal computed tomography scan, showing local disease regression within the left inguinal area, with infiltration of the left bladder wall|
Click here to view
|Figure 2: Lower abdominal computed tomography scan, showing metastatic spread to the left testicle, with prominent scrotum enlargement|
Click here to view
The patient's clinical condition ameliorated after the surgery, with significant pain reduction. Immunotherapy was continued, but in May 2019, disease progression was observed, and the patient was set in third-line treatment with vinflunine.
| Discussion|| |
We report the case of an urothelial carcinoma of the left lower ureter, with metastasis to the collateral testicle, as the first manifestation of distant metastatic disease. Since its clinical presentation was mimicking an acute orchiepididymitis, it misled physicians with consequent delay in antineoplastic treatment provision.
Misleading testicular metastasis from urothelial carcinomas of the upper urinary tract, mimicking orchiepididymitis, have been already reported in literature, both for upper and lower ureteral locations [Table 1].,,,
|Table 1: Table summarizing reported cases of ureteral carcinomas giving testicular metastases, initially misdiagnosed as orchiepididymitis|
Click here to view
Hence, the question is how we can suspect and explain this unusual metastatic spread to provide a prompt and timely anticancer treatment. Genitourinary anatomy and timing are probably the two most important tools that can help physicians in differentiating diagnosis between testicular neoplastic metastatic spread and an orchiepididymitis.
With respect to anatomy, metastatic neoplastic disease generally occurs through vascular, lymphovascular, and direct spread of malignancies. Since reverse blood and lymph flow may be noted in various physiologic and pathological conditions,“reversal flow location metastasis” may develop. Testicular“reverse-flow” metastatic spread from lower, median, and upper ureteral and pelvic malignancies may follow two different blood/lymphatic reverse flow routes. Left ureteral and pelvic neoplasms may spread to the ipsilateral testicle through of lymphatic/vascular reticulum and through reverse blood flow from the left renal to the left testicular vein.,,, Similarly, and for both sides, a malignancy of the inferior part of the ureter (i.e., ureteral loop and ureteral bladder implant) may directly invade nearby organs, the seminal vesicle and last part of vas deferens, and afterward spread to the ipsilateral testicle through the deferens duct and its lymphatic/vascular domains. In our case, disease extended within the bladder cuff, compromising surgical limits, and subsequently spreading to the urogenital system through infiltration of the left seminal vesicle and the left vas deferens.
Timing is not a redundant issue. Although an orchiepididymitis may potentially affect any individual, such a diagnosis following soon after a surgery or a diagnosis of a locally advanced cancer of the ureter should raise clinical suspicion of a potential reverse flow metastatic spread, and the possibility of malignancy should be included in the differential diagnosis algorithm.
Of note, the immunophenotype of the primary neoplasm was compatible with p-53-like and basal-like urothelial carcinoma, two molecular subtypes associated with rapid disease dissemination and resistance to treatment as well as squamous histologic differentiation, also described in the testicular metastatic site.
In conclusion, time from oncological detection/management and knowledge in blood and lymph reverse flow routes may avoid misleading diagnoses and cancer treatment delays of testicular metastasis from ureteral carcinomas mimicking orchiepididymitis.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
The authors have nothing to acknowledge.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al
. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 2018;73:111-22.
Arora HC, Fascelli M, Zhang JH, Isharwal S, Campbell SC. Kidney, ureteral, and bladder cancer: A primer for the internist. Med Clin North Am 2018;102:231-49.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30.
Shinagare AB, Fennessy FM, Ramaiya NH, Jagannathan JP, Taplin ME, van den Abbeele AD. Urothelial cancers of the upper urinary tract: Metastatic pattern and its correlation with tumor histopathology and location. J Comput Assist Tomogr 2011;35:217-22.
Wu XW, Zhang Y, Li YF, Li Y, Zhang XX, Wang W, et al
. Testicular metastasis from urothelial carcinoma of the renal pelvis: A rare case and review of the literature. Onco Targets Ther 2020;13:915-20.
Manav AN, Kazan E, Ertek MŞ, Amasyalı AS, Culhacı N, Erol H. A rare cause of testicular metastasis: Upper tract urothelial carcinoma. Case Rep Urol 2014;2014:3.
Wang CN, Huang CN, Hsiao PH, Chou YH, Huang CH. An unusual testicular metastasis from transitional cell carcinoma of the ureter: A case report. Gaoxiong Yi Xue Ke Xue Za Zhi 1995;11:578-81.
Kubiak M, Klein J, de Perrot T, Tille JC, Iselin CE. Testicular metastasis of a upper urinary tract high-grade papillary urothelial carcinoma, 2 Years after nephroureterectomy. Urol Case Rep 2016;4:25-6.
[Figure 1], [Figure 2]